Kinase inhibitors are among the fastest growing class of anti-cancer therapies. One family of kinases that has
recently gained attention as a target for treating malignant disorders is the Tec kinase family. Evidence has been published
that one member of this family; the Bmx kinase, may play a role in the pathogenesis of glioblastoma, prostate, breast and
lung cancer. Bmx has also shown potential as an anti-vascular therapy in combination with radiation or as a sensitizer to
chemotherapeutic agents. Therefore, several companies such as Pharmacyclics, Avila Therapeutics, Merck and Co.,
Metaproteomics, IRM, and Moerae Matrix have developed compounds or peptides that function as Bmx kinase inhibitors.
These companies have subsequently been issued patents for these inhibitors. Additionally, it has been shown that current
clinical stage EGFR inhibitors can irreversibly inhibit Bmx, suggesting these compounds might be rapidly moved to clinical
trials for other malignancies. This review will discuss current patents issued since 2009 that contain data specifically
on inhibition of the Bmx kinase, and will also discuss the scientific literature that suggests their potential application as
therapeutics in the treatment of the aforementioned malignancies.
Keywords: Bmx, breast cancer, Btk, Etk, glioblastoma, kinase inhibitor, lung cancer, prostate cancer, Tec.
Rights & PermissionsPrintExport